MetaCap

Fortrea Holdings Inc. (FTRE)

NASDAQ: FTREHealth CareMedical SpecialitiesUSD

18.55-1.60 (-7.94%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

FTRE stock chart

Technical analysis

Key statistics

All statistics
EPS (TTM)
-$0.73
52-week range
8.55 – 26.16
Day range
18.30 – 20.52
Volume / Avg
1.54M / 1.69M
Beta
—

52-week range

$8.55$26.16

FTRE stock today

Fortrea (FTRE) closed at $18.55 on Nov 20, down 7.94% (-$1.60), versus the S&P 500's 3.70% decline. Shares are 29.1% below their 52-week high of $26.16, set on Oct 28, 2026 and 117.0% above the 52-week low of $8.55, in the middle of the past year's range. FTRE is up 7.5% year to date, outperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has gained 70.2%.

Fortrea has posted a net loss over the last twelve months (EPS of -$0.73), so its P/E ratio is not meaningful.

Summary generated from market data by MetaCap's automated system. Methodology

About Fortrea

Company profile

Fortrea Holdings Inc., a contract research organization, provides biopharmaceutical product and medical device development solutions to pharmaceutical, biotechnology, and medical device customers worldwide. It offers clinical pharmacology, such as clinical research units, external partnerships, project management, study design and monitoring, bioanalytics and biomarkers, pharmacokinetics, modeling and simulation, and biometrics; and clinical development, including phase I through IV clinical and real-world evidence studies, regulatory affairs, protocol design, operational planning, study and site start-up, patient recruitment, project management, comprehensive site and medical monitoring, data management and biostatistics, pharmacovigilance, medical writing, and mobile clinical services. The company also provides consulting services comprising product development and regulatory, market access and health economics, and outcomes research, as well as RWE services.

Industry
Medical Specialities
CEO
Mr. Anshul Thakral
Headquarters
Durham, NC
Employees
14,000

Financial highlights

Full financials

In fiscal 2025, Fortrea generated $2.72 billion in revenue, up 1.0% from fiscal 2024. Fortrea reported a net loss of $986.2 million, compared with a loss of $328.5 million a year earlier. Gross margin was 18.5% (down from 19.8%) and operating margin -32.0%.

Fortrea annual revenue, net income and EPS
Fiscal yearFY 2025FY 2024FY 2023FY 2022FY 2021
Revenue$2.72B$2.70B$2.84B$2.84B$3.06B
Growth+1.00%-5.14%+0.19%-7.21%—
Net income$-986.20M$-328.50M$-25.20M$186.20M$98.00M
EPS (diluted)$-10.81$-3.67$-0.29$2.09$1.10

Analyst forecast

Forecast

Consensus (13 analysts)

buy

Avg. price target

$23.63+27.39%

  • Strong buy 1
  • Buy 6
  • Hold 3
  • Sell 1
  • Strong sell 2

Target range

Low $13.50High $29.00

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Last reported (Sep/2026)
Oct 29, 2026
EPS actual vs est.
$0.01 vs $0.24
Surprise
-95.83%

FTRE news

All FTRE news

Fortrea peers

Health Care sector
FTRE peer companies
CompanyPrice% ChgMarket capCompare
CLOVClover Health Investments Corp. Class A3.73-1.06%$2.00Bvs FTRE
VCYTVeracyte Inc.25.13+0.36%$2.03Bvs FTRE
PSNLPersonalis Inc.14.27-3.06%$1.55Bvs FTRE
TRUPTrupanion Inc.35.56-0.86%$1.54Bvs FTRE
LMRILumexa Imaging Holdings Inc.14.26+1.42%$1.37Bvs FTRE
ALHCAlignment Healthcare Inc.6.37-2.00%$1.33Bvs FTRE
FRNMFreenome Inc.9.36-5.69%$1.04Bvs FTRE
CSTLCastle Biosciences Inc.32.86-1.63%$1.01Bvs FTRE

Indexes, lists and sector

Fortrea stock FAQ

What is Fortrea's stock price today?

FTRE last traded at $18.55 as of Nov 20, 4:00 PM EST, down 7.94% on the day. Prices are delayed at least 15 minutes.

Who is Fortrea's CEO?

Mr. Anshul Thakral is the chief executive officer of Fortrea Holdings Inc., which has about 14,000 employees.

What is the FTRE 52-week high?

The 52-week high for FTRE is $26.16 and the 52-week low is $8.55. The stock is currently 29.1% below its high.

Compare FTRE